Novel Estrogenic Compounds
First Claim
1. A topical pharmaceutical formulation comprising:
- (a) a compound represented by the following Formula;
or pharmaceutically acceptable salts thereof wherein;
R and R1 are each independently hydrogen, sulfate or glucuronide and said compound has the following physicochemical properties;
(i) a peak located at about 1.2 ppm in a 1H-NMR spectrum; and
(ii) a peak located at about 45 ppm in a 13C-NMR spectrum. said compound being present in chemically pure form; and
(b) a pharmaceutically active ingredient selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts, and vitamin D, and mixtures and combinations thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
Novel estrogenic compounds of Formula I are provided.
wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an α or a β orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
-
Citations
10 Claims
-
1. A topical pharmaceutical formulation comprising:
-
(a) a compound represented by the following Formula; or pharmaceutically acceptable salts thereof wherein; R and R1 are each independently hydrogen, sulfate or glucuronide and said compound has the following physicochemical properties; (i) a peak located at about 1.2 ppm in a 1H-NMR spectrum; and (ii) a peak located at about 45 ppm in a 13C-NMR spectrum. said compound being present in chemically pure form; and (b) a pharmaceutically active ingredient selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts, and vitamin D, and mixtures and combinations thereof. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A topical pharmaceutical formulation comprising:
-
(a) a compound represented by the following Formula; or pharmaceutically acceptable salts thereof wherein; R, R1 and R2 are each independently hydrogen, sulfate or glucuronide and said compound has the following physicochemical properties; (i) a peak located at about 1.2 ppm in a 1H-NMR spectrum; and (ii) a peak located at about 45 ppm in a 13C-NMR spectrum. said compound being present in chemically pure form; and (b) a pharmaceutically active ingredient selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts, and vitamin D, and mixtures and combinations thereof. - View Dependent Claims (7, 8, 9, 10)
-
Specification